Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Orthocell accelerates global market expansion of Striate+™ and Remplir™
MP3•Episode home
Manage episode 430467170 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Orthocell Ltd (ASX:OCC) has seven regulatory applications in progress or planned, targeting approval in significant markets. Striate+™, used for guided bone and tissue regeneration, is gaining traction in the US, Europe/UK, Australia and Canada. Orthocell aims to obtain approval in Brazil and Singapore within 6-12 months. Remplir™, designed for peripheral nerve repair, is already approved in Australia, with regulatory clearance in Singapore and the US expected within 6-9 months. Applications for Canada, Thailand and the EU/UK are also planned within the next year. The global market opportunity for Striate+™ and Remplir™ is estimated to exceed US$3 billion. With Striate+™ achieving a 98.6% success rate in clinical studies, Orthocell, in partnership with BioHorizons Implant Systems Inc, is focusing on market expansion. Striate+™ is anticipated to secure significant market share in existing and new markets. For Remplir™, the product has gained positive feedback from surgeons in Australia and New Zealand, and Orthocell is on track to expand into the US and Singapore, with further expansion planned in ASEAN markets and Canada. Orthocell’s strong balance sheet of $20.6 million positions the company well for expanding its commercial footprint and growing product adoption and revenues. #ProactiveInvestors #Orthocell #ASX #MedicalDevices, #StriatePlus, #Remplir, #RegenerativeMedicine, #MarketExpansion, #DentalImplants, #NerveRepair, #RegulatoryApproval, #HealthcareInnovation, #BioHorizons, #GlobalMarkets, #Healthcare, #ClinicalSuccess, #USMarket, #EuropeMarket, #AustraliaMarket, #SingaporeMarket, #MedicalTechnology, #HealthSolutions #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
610 episodes
MP3•Episode home
Manage episode 430467170 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Orthocell Ltd (ASX:OCC) has seven regulatory applications in progress or planned, targeting approval in significant markets. Striate+™, used for guided bone and tissue regeneration, is gaining traction in the US, Europe/UK, Australia and Canada. Orthocell aims to obtain approval in Brazil and Singapore within 6-12 months. Remplir™, designed for peripheral nerve repair, is already approved in Australia, with regulatory clearance in Singapore and the US expected within 6-9 months. Applications for Canada, Thailand and the EU/UK are also planned within the next year. The global market opportunity for Striate+™ and Remplir™ is estimated to exceed US$3 billion. With Striate+™ achieving a 98.6% success rate in clinical studies, Orthocell, in partnership with BioHorizons Implant Systems Inc, is focusing on market expansion. Striate+™ is anticipated to secure significant market share in existing and new markets. For Remplir™, the product has gained positive feedback from surgeons in Australia and New Zealand, and Orthocell is on track to expand into the US and Singapore, with further expansion planned in ASEAN markets and Canada. Orthocell’s strong balance sheet of $20.6 million positions the company well for expanding its commercial footprint and growing product adoption and revenues. #ProactiveInvestors #Orthocell #ASX #MedicalDevices, #StriatePlus, #Remplir, #RegenerativeMedicine, #MarketExpansion, #DentalImplants, #NerveRepair, #RegulatoryApproval, #HealthcareInnovation, #BioHorizons, #GlobalMarkets, #Healthcare, #ClinicalSuccess, #USMarket, #EuropeMarket, #AustraliaMarket, #SingaporeMarket, #MedicalTechnology, #HealthSolutions #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
610 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.